{"id":38725,"date":"2026-06-11T11:10:00","date_gmt":"2026-06-11T15:10:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38725"},"modified":"2026-05-04T16:11:53","modified_gmt":"2026-05-04T20:11:53","slug":"formulating-success-how-pharma-companies-engineer-around-expiring-drug-patents-before-the-generic-cliff-hits","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/formulating-success-how-pharma-companies-engineer-around-expiring-drug-patents-before-the-generic-cliff-hits\/","title":{"rendered":"Formulating Success: How Pharma Companies Engineer Around Expiring Drug Patents Before the Generic Cliff Hits"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Every major drug company has a clock running in its boardroom. When a blockbuster patent expires, billions in annual revenue can evaporate within months as generic manufacturers flood the market. The industry calls it the ‘patent cliff,’ and it is not a metaphor. Between 2025 and 2030, patents protecting drugs generating an estimated $200 billion in annual global sales will expire [1]. The companies that survive those transitions intact are rarely the ones that simply watched the calendar. They are the ones that started engineering around their own patents years in advance.<\/p>\n\n\n\n

Design-around strategies, the deliberate reformulation, repackaging, and repositioning of drug products before generic entry, have become one of the most consequential disciplines in pharmaceutical business strategy. Done well, a design-around can preserve 40 to 70 percent of a brand’s revenue after patent expiration [2]. Done poorly, or not done at all, a company hands competitors a blueprint for displacement and watches market share collapse in a matter of quarters.<\/p>\n\n\n\n

This article walks through the full landscape of design-around options available to pharmaceutical companies: the formulation science behind them, the legal frameworks that make them defensible, the regulatory pathways that extend their market life, and the competitive intelligence infrastructure, including tools like DrugPatentWatch, that companies use to map the terrain before committing to a strategy.<\/p>\n\n\n\n

\n\n\n\n

The Patent Cliff Is Not a Natural Disaster. It Is a Scheduled Event.<\/strong><\/h2>\n\n\n\n

The pharmaceutical industry treats patent expiration with a peculiar combination of dread and denial. Dread because the financial consequences are immediate and measurable. Denial because, for many large organizations, the political and structural barriers to cannibalizing your own franchise are enormous.<\/p>\n\n\n\n

Consider what happened to AstraZeneca’s Nexium (esomeprazole) after its core composition patent expired in May 2014. The company had spent years converting patients from Prilosec (omeprazole) to Nexium by positioning the S-enantiomer as clinically superior, a strategy that generated over $6 billion in annual U.S. sales at peak. When generics entered the market, the brand lost roughly 80 percent of its prescription volume within eighteen months [3]. What is instructive is not the loss, but the fact that AstraZeneca had seen it coming for a decade and still failed to fully neutralize it through product lifecycle management.<\/p>\n\n\n\n

Contrast that with Abbott’s management of TriCor (fenofibrate). Abbott launched four successive reformulations of fenofibrate across roughly fifteen years, each timed to coincide with anticipated generic entry against the prior version. The company migrated patients from the original 67mg capsule to a 200mg capsule, then to a 145mg tablet with improved bioavailability, and later to a nanoparticle-based formulation. Each switch involved regulatory approval, new patent coverage, and aggressive formulary management with payers. The Federal Trade Commission eventually scrutinized these practices in an antitrust complaint alleging that Abbott’s product-hopping strategy unfairly suppressed generic competition [4]. That complaint itself reveals something important: these strategies are effective enough to attract regulatory attention.<\/p>\n\n\n\n

What ‘Design-Around’ Actually Means in Practice<\/strong><\/h3>\n\n\n\n

The term ‘design-around’ originated in general patent law and refers to any effort by a party to design a product or process that accomplishes the same functional goal as a patented invention without infringing the patent’s claims. In pharmaceuticals, the concept applies in two distinct directions.<\/p>\n\n\n\n

The first is defensive design-around, where a brand manufacturer engineers new versions of its own drug to build additional patent protection layers before generic entry. The second is offensive design-around, where a generic manufacturer attempts to develop a product that is bioequivalent to the reference listed drug without triggering infringement claims. This article focuses primarily on the brand-side defensive approach, though both directions inform the competitive dynamic.<\/p>\n\n\n\n

Defensive design-around strategies in pharma cluster into four broad categories:<\/p>\n\n\n\n

    \n
  • Formulation changes: modified-release systems, new delivery technologies, particle engineering, and fixed-dose combinations<\/li>\n\n\n\n
  • New chemical entity derivatives: active metabolites, prodrugs, enantiomers, and polymorph conversions<\/li>\n\n\n\n
  • New indications: regulatory exclusivities triggered by pediatric studies, orphan designation, or genuinely new therapeutic uses<\/li>\n\n\n\n
  • Delivery system innovations: device-drug combinations, transdermal patches, implants, and proprietary inhalation platforms<\/li>\n<\/ul>\n\n\n\n

    Each category carries its own scientific, regulatory, legal, and commercial requirements. The most successful lifecycle management programs layer multiple approaches simultaneously, creating what patent attorneys call a ‘patent thicket,’ a cluster of overlapping patents covering different aspects of the product that collectively delay generic entry even when any individual patent might be challenged successfully.<\/p>\n\n\n\n

    \n\n\n\n

    Reading the Patent Landscape Before You Formulate<\/strong><\/h2>\n\n\n\n

    No design-around strategy can be built without a precise understanding of which patents are in place, which are vulnerable to challenge, and which claims are broad enough to constrain reformulation options. This is where competitive intelligence infrastructure becomes the foundation of the entire effort.<\/p>\n\n\n\n

    DrugPatentWatch is among the most widely used platforms for this work. The service aggregates FDA Orange Book patent listings, Paragraph IV certification filings, patent expiration dates, and litigation history into a searchable database that allows R&D and business development teams to map a drug’s full intellectual property exposure in a matter of hours rather than weeks. For any compound under lifecycle management consideration, the starting point is understanding not just when the composition-of-matter patent expires, but what formulation patents, method-of-use patents, and process patents remain active, and when each is vulnerable to inter partes review or Paragraph IV challenge.<\/p>\n\n\n\n

    The Orange Book, formally the FDA’s ‘Approved Drug Products with Therapeutic Equivalence Evaluations,’ is the statutory mechanism through which brand manufacturers list patents they believe would be infringed by a generic. Orange Book listings are strategic documents as much as legal ones. A brand company that lists a patent in the Orange Book forces any ANDA (Abbreviated New Drug Application) filer to either wait for the patent to expire or certify that it is invalid or will not be infringed, triggering a potential 30-month stay of FDA approval [5]. That 30-month stay is a substantial competitive lever.<\/p>\n\n\n\n

    What DrugPatentWatch and similar services expose is the gap between what is listed in the Orange Book and what is actually protecting a franchise. A composition-of-matter patent on the active pharmaceutical ingredient is the strongest protection a company can have. When that expires, the question becomes whether the remaining formulation, method-of-use, and secondary patents can withstand challenge, and whether they represent genuine innovation or merely extend exclusivity without meaningful clinical benefit.<\/p>\n\n\n\n

    The Orange Book as a Strategic Instrument<\/strong><\/h3>\n\n\n\n

    The FDA has specific rules about which patents qualify for Orange Book listing. A patent must claim the drug substance, the drug product (including formulation), or an approved method of using the drug [6]. Process patents, metabolite patents for metabolites not themselves approved drugs, and patents claiming packaging do not qualify. Within those constraints, brand manufacturers have historically been aggressive about listing every qualifying patent they can.<\/p>\n\n\n\n

    A company preparing a design-around strategy will typically conduct what practitioners call a ‘white space analysis,’ a systematic review of the existing patent landscape to identify formulation or delivery approaches that would not infringe existing third-party patents while still supporting new proprietary protection. This analysis is not optional. Without it, a company can invest years and hundreds of millions in developing a new formulation only to discover that the approach is already claimed by a competitor or, worse, that the new formulation patents will not survive validity challenge because the underlying science was obvious at the time of filing.<\/p>\n\n\n\n

    \n

    ‘Brand pharmaceutical companies face a fundamental tension: the same transparency that makes the patent system work also gives competitors a precise roadmap for designing around your protections. The companies that manage this best treat patent intelligence not as a legal function but as a business strategy function.’<\/p>\n\n\n\n

    Kesselheim AS, Avorn J. ‘The Most Transformative Drugs of the Past 25 Years: A Survey of Physicians.’ Nature Medicine, 2013 [7]<\/p>\n<\/blockquote>\n\n\n\n

    The timing of when to initiate a design-around program relative to patent expiration is itself a strategic variable. Starting too early wastes resources on a franchise that may not need protection. Starting too late leaves insufficient time to generate the clinical, manufacturing, and regulatory data needed to support new patent filings and FDA approval. Most practitioners in the field recommend beginning the landscape analysis five to seven years before the composition-of-matter patent expiration and committing to specific reformulation tracks no later than three to four years out [8].<\/p>\n\n\n\n

    \n\n\n\n

    Formulation Science as Competitive Strategy<\/strong><\/h2>\n\n\n\n

    The science of pharmaceutical formulation has advanced dramatically over the past two decades. What was once primarily a manufacturing concern, how to make a pill that dissolves consistently and delivers the right dose, has become a rich source of intellectual property with genuine clinical differentiation potential. The companies that understand this distinction, between formulation innovation that is merely patent-extending and formulation innovation that is genuinely better for patients, navigate both the regulatory and competitive environment more effectively.<\/p>\n\n\n\n

    Modified-Release Systems<\/strong><\/h3>\n\n\n\n

    Extended-release, controlled-release, and delayed-release formulations represent the most commonly deployed design-around tool in the pharma toolkit. The underlying logic is straightforward: a drug that maintains therapeutic blood levels over 24 hours with a single daily dose is clinically preferable to the same compound requiring dosing three or four times daily. If the original product required multiple daily doses, a once-daily formulation can represent a legitimate clinical advance, command premium pricing, and support a new patent estate covering the release technology.<\/p>\n\n\n\n

    The poster case for this approach is methylphenidate. The molecule itself has been off-patent for decades. Yet Alza Corporation’s OROS (Osmotic Release Oral System) technology, licensed to various manufacturers, enabled the development of Concerta, a once-daily formulation using an osmotic pump delivery system that maintains predictable drug release over 8 to 12 hours [9]. The proprietary delivery technology, rather than the molecule, became the basis for commercial differentiation and patent protection. Concerta maintained substantial market share for years after methylphenidate IR generics were available at a fraction of the price, primarily because the OROS mechanism was not easily replicated by generic manufacturers using standard bioequivalence testing.<\/p>\n\n\n\n

    Jansen’s Risperdal Consta represents a different modified-release approach: microsphere-based extended-release injectable risperidone. The original oral risperidone molecule (Risperdal) went off-patent, but the injectable long-acting formulation supported distinct IP protection, distinct clinical positioning around adherence in schizophrenia management, and distinct reimbursement negotiations with payers [10]. The formulation science created a product that was genuinely clinically different, not merely patent-extended.<\/p>\n\n\n\n

    The distinction matters for two reasons. First, payers and formulary committees have become increasingly sophisticated at identifying formulation changes they view as primarily exclusivity-extending rather than clinically meaningful. Products that cannot demonstrate outcomes-level differentiation face pressure on formulary placement and rebate negotiations regardless of their patent status. Second, the FTC’s increasing scrutiny of ‘product hopping,’ which involves switching patients to new formulations timed to generic entry on the prior version, has created legal risk for strategies perceived as anticompetitive rather than genuinely innovative.<\/p>\n\n\n\n

    Particle Engineering and Nanoparticle Technologies<\/strong><\/h3>\n\n\n\n

    Reducing particle size increases the surface area available for dissolution, which can improve bioavailability for poorly water-soluble compounds. Nanotechnology-based drug delivery, including nanocrystal technology and nanoparticle formulations, has enabled reformulations of existing compounds that achieve therapeutic plasma concentrations at lower doses, with food-independent absorption, or with faster onset of action.<\/p>\n\n\n\n

    Elan Corporation (later acquired by Perrigo) developed NanoCrystal technology, which was licensed across multiple compounds. Rapamune (sirolimus) in its nanocrystal tablet formulation offered improved bioavailability compared to the original oral solution, allowing for a 20 percent dose reduction while maintaining clinical equivalence [11]. The FDA considers the nanocrystal tablet and the oral solution to be clinically non-equivalent, meaning generic manufacturers cannot use the oral solution as a reference listed drug for the tablet formulation. That regulatory designation creates additional time for the brand even after the molecular patent expires.<\/p>\n\n\n\n

    TriCor’s evolution through Abbott’s lifecycle management program included a nanoparticle version (Tricor 145mg) that allowed food-independent dosing, removing the requirement to take the drug with food that characterized earlier formulations. This addressed a genuine compliance barrier for patients and created pharmacokinetic data supporting new patent claims [12]. As noted earlier, the FTC disputed whether the cumulative effect of Abbott’s reformulation strategy was competitive or anticompetitive. The scientific and clinical substance of the individual formulation improvements, however, was not in serious dispute.<\/p>\n\n\n\n

    Fixed-Dose Combinations<\/strong><\/h3>\n\n\n\n

    Combining two or more active pharmaceutical ingredients in a single dosage form is a legitimate clinical strategy for conditions where patients routinely require both agents. Fixed-dose combinations simplify treatment regimens, potentially improve adherence, and in some cases offer pharmacokinetic advantages over the separate components. They also generate a new regulatory package (requiring a full NDA or supplement demonstrating clinical benefit of the combination), new patent coverage for the combination itself, and a new commercial cycle.<\/p>\n\n\n\n

    The HIV antiretroviral market has been built largely on fixed-dose combination strategies. Gilead Sciences’ Atripla combined efavirenz, emtricitabine, and tenofovir disoproxil fumarate into a single once-daily pill. Each component had existing patent protection, but the combination, along with the clinical data demonstrating its efficacy and safety as a single-tablet regimen, created distinct IP and enabled Gilead to command premium pricing and payer support that would not have been achievable by any individual component alone [13]. Subsequent combination products, Complera, Stribild, Genvoya, and Biktarvy, each built on prior generations while introducing newer agents with longer patent life, creating a rolling cycle of combination products that maintained Gilead’s HIV franchise revenue even as earlier-generation components faced generic competition.<\/p>\n\n\n\n

    The cardiovascular space has seen similar dynamics. The combination of amlodipine and atorvastatin in Caduet (Pfizer) addressed a patient population frequently prescribed both drugs individually, combined them in a single pill, and generated a new patent estate and a new FDA approval [14]. The combination itself was not scientifically complex, but the regulatory process of demonstrating safety and efficacy for the combination product, and the resulting Orange Book listings, created additional exclusivity that the individual components alone could not support.<\/p>\n\n\n\n

    \n\n\n\n

    The Chemistry of Design-Around: NCE Derivatives<\/strong><\/h2>\n\n\n\n

    Moving from formulation changes to modifications of the molecular entity itself represents a higher-risk, higher-reward tier of design-around strategy. New chemical entity derivatives, including active metabolites, prodrugs, enantiomers, and salt forms, can generate composition-of-matter patent protection that is substantially stronger than formulation patents and harder for generic manufacturers to work around.<\/p>\n\n\n\n

    Active Metabolites<\/strong><\/h3>\n\n\n\n

    When the body metabolizes a drug, the resulting metabolites are sometimes pharmacologically active. If an active metabolite can be developed as a standalone drug, it may represent a distinct new chemical entity eligible for its own composition-of-matter patent, independent clinical development, and separate FDA approval with new exclusivity periods.<\/p>\n\n\n\n

    The classic case is fexofenadine (Allegra), the active metabolite of terfenadine (Seldane). Seldane was a first-generation antihistamine that was voluntarily withdrawn from the market in 1998 due to cardiac side effects from drug-drug interactions [15]. Hoechst Marion Roussel had already developed fexofenadine, the active metabolite responsible for Seldane’s antihistamine effect, as an independent compound. Because fexofenadine did not carry Seldane’s cardiac liability, it became a commercially successful antihistamine in its own right, with a new patent estate entirely independent of the original terfenadine composition patent.<\/p>\n\n\n\n

    Escitalopram (Lexapro, Forest Laboratories) is the S-enantiomer of citalopram (Celexa), itself a racemic mixture of R- and S-enantiomers. Forest’s argument for escitalopram was that the S-enantiomer accounted for most of citalopram’s antidepressant effect with a more favorable side effect profile. Whether that clinical argument was fully supported by head-to-head data was debated extensively in the psychiatric literature. What is less debatable is that escitalopram had its own composition-of-matter patent, its own FDA approval, its own New Chemical Entity exclusivity, and its own commercial life that extended well beyond citalopram’s patent expiry [16].<\/p>\n\n\n\n

    Prodrugs<\/strong><\/h3>\n\n\n\n

    A prodrug is a pharmacologically inactive compound that is converted to the active drug in the body through metabolic processes. Developing a prodrug of an existing active pharmaceutical ingredient can provide formulation advantages, including improved oral bioavailability, reduced local irritation, or modified pharmacokinetic profiles, while generating entirely new composition-of-matter claims.<\/p>\n\n\n\n

    Tenofovir alafenamide (TAF) is the prodrug successor to tenofovir disoproxil fumarate (TDF), the active ingredient in multiple Gilead HIV combination products. TAF was developed as a more stable and efficient prodrug that delivers tenofovir to lymphoid cells at lower plasma concentrations than TDF, theoretically reducing kidney and bone toxicity [17]. Gilead filed numerous patents covering TAF itself, its pharmaceutical compositions, and methods of treatment. Those patents were entirely distinct from the TDF patent estate and supported a new generation of HIV combination products, Genvoya, Descovy, and Biktarvy, at a time when TDF-containing products faced patent challenges.<\/p>\n\n\n\n

    The strategic logic was clear: by developing a genuinely better-performing prodrug and accumulating new patent protection around it, Gilead was positioned to migrate patients from aging TDF-containing regimens to newer TAF-containing products with fresh exclusivity, even as TDF generics entered the market. The TAF strategy also carried clinical credibility because the real-world kidney and bone safety data supported the theoretical advantage of lower systemic tenofovir exposure.<\/p>\n\n\n\n

    Polymorphs and Salt Forms<\/strong><\/h3>\n\n\n\n

    Many drug molecules can exist in multiple crystalline forms (polymorphs) or as different salts, each with potentially distinct physical and chemical properties affecting solubility, stability, and bioavailability. Patent protection for specific polymorphs or salt forms has been used to extend commercial exclusivity beyond the underlying molecular patent.<\/p>\n\n\n\n

    Clopidogrel bisulfate (Plavix, Sanofi\/Bristol-Myers Squibb) was protected in part by a patent covering its bisulfate salt form. When generic manufacturers attempted to develop clopidogrel in alternative salt forms to avoid infringement, they encountered both technical challenges and additional patent disputes about which forms were covered. The clopidogrel litigation generated over a decade of patent battles and is among the most heavily litigated pharmaceutical patent cases in U.S. history, involving challenges to multiple Orange Book-listed patents across multiple jurisdictions [18].<\/p>\n\n\n\n

    The Indian Supreme Court’s 2013 decision in Novartis AG v. Union of India is the most prominent international case on polymorph patentability. The court rejected Novartis’s patent application for the beta crystalline form of imatinib mesylate (Gleevec\/Glivec) under Section 3(d) of India’s Patents Act, which requires that new forms of known substances demonstrate enhanced efficacy rather than merely different physical properties [19]. The decision has had substantial influence on patent law in developing countries and has informed ongoing debates in developed markets about where to draw the line between genuine molecular innovation and purely administrative intellectual property extension.<\/p>\n\n\n\n

    \n\n\n\n

    Regulatory Exclusivity as an Independent Defense Layer<\/strong><\/h2>\n\n\n\n

    Patent protection and regulatory exclusivity are legally distinct mechanisms that operate on parallel tracks. A company can have neither, one, or both for any given product. Understanding how regulatory exclusivity interacts with patent expiration is essential to lifecycle management planning.<\/p>\n\n\n\n

    New Chemical Entity Exclusivity<\/strong><\/h3>\n\n\n\n

    The FDA grants five years of data exclusivity to approved New Chemical Entities, compounds that contain an active moiety not previously approved in any form [20]. During those five years, no ANDA can be filed referencing the NCE’s safety and efficacy data. For NMEs that also hold strong composition-of-matter patents, NCE exclusivity adds a baseline protection floor. For NMEs without robust patent protection, it may be the primary exclusivity period available.<\/p>\n\n\n\n

    Pediatric Exclusivity<\/strong><\/h3>\n\n\n\n

    The Best Pharmaceuticals for Children Act provides six months of additional exclusivity to sponsors who complete FDA-requested pediatric studies [21]. Those six months attach to any existing patents or exclusivities listed in the Orange Book, effectively extending all other protections by six months. For a blockbuster drug generating $5 billion annually, six months of additional exclusivity is worth roughly $2.5 billion in protected revenue, a return that dwarfs the cost of conducting the pediatric studies.<\/p>\n\n\n\n

    Pediatric exclusivity has been used extensively. By 2020, the FDA had issued over 800 written requests for pediatric studies under BPCA, and more than 600 products had received pediatric labeling changes as a result [22]. The program generates genuine public health value, as pediatric dosing data were frequently absent from approved labeling prior to the incentive. That the exclusivity extension is commercially valuable does not undermine the clinical utility of the underlying data generation.<\/p>\n\n\n\n

    Orphan Drug Exclusivity<\/strong><\/h3>\n\n\n\n

    The Orphan Drug Act grants seven years of market exclusivity for drugs treating diseases or conditions affecting fewer than 200,000 patients in the United States [23]. During those seven years, the FDA may not approve another application for the same drug for the same orphan indication, with limited exceptions. For a company whose drug has applications in both orphan and non-orphan conditions, an orphan designation in an eligible indication creates a valuable exclusivity layer that operates independently of patents.<\/p>\n\n\n\n

    Alexion Pharmaceuticals built its entire commercial foundation on orphan drug exclusivity for Soliris (eculizumab) in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). When Soliris faced patent challenges and eventual expiration, Alexion had developed Ultomiris (ravulizumab), a modified eculizumab with an extended half-life allowing less frequent dosing, supported by new orphan designations, new clinical data, and new patents [24]. The Alexion model illustrates both the power of layered exclusivity strategies and the vulnerability of relying too heavily on a single product with a finite IP runway.<\/p>\n\n\n\n

    Three-Year Exclusivity for New Clinical Investigations<\/strong><\/h3>\n\n\n\n

    Beyond the five-year NCE exclusivity, the FDA grants three years of exclusivity for approved NDA supplements or new NDAs that required new clinical investigations essential to approval [25]. This covers new indications, new dosage forms, new strengths, and new patient populations. A company that develops a new formulation requiring new clinical data to demonstrate safety or efficacy can obtain three-year exclusivity for that specific product configuration, blocking generic ANDA filers from referencing the new clinical data during the exclusivity period.<\/p>\n\n\n\n

    Three-year exclusivity is not as powerful as NCE exclusivity because generic manufacturers can reference the original NDA and seek approval for the original formulation rather than the new one. But when combined with new Orange Book-listed patents covering the new formulation, three-year exclusivity creates a meaningful additional protection window for the new product iteration.<\/p>\n\n\n\n

    \n\n\n\n

    Delivery System Innovations: Devices, Patches, and Platform Technologies<\/strong><\/h2>\n\n\n\n

    Some of the most durable and commercially successful design-around strategies involve transforming a conventional oral or injectable drug into a device-based delivery system. Drug-device combinations require separate regulatory approval pathways, generate device patents in addition to pharmaceutical patents, and create manufacturing and formulation complexity that generic manufacturers struggle to replicate.<\/p>\n\n\n\n

    Inhalation Drug Delivery<\/strong><\/h3>\n\n\n\n

    The respiratory drug market has been shaped by proprietary inhaler technologies as much as by the active pharmaceutical ingredients they deliver. GlaxoSmithKline’s Advair Diskus, combining fluticasone propionate and salmeterol in a dry powder inhaler device, dominated the inhaled corticosteroid\/long-acting beta agonist market for years. When the active ingredient patents expired, the proprietary Diskus device itself, the formulation of the powder blend, and the regulatory complexity of demonstrating device equivalence created substantial barriers to generic entry [26].<\/p>\n\n\n\n

    The FDA’s pathway for approving generic combination drug-device products requires demonstration not only of pharmaceutical bioequivalence but of device equivalence as well. Regulators need to be satisfied that the generic inhaler delivers drug to the same pulmonary regions in the same particle size distribution as the reference product. This requirement imposed years of additional development work and regulatory uncertainty on would-be generic entrants. Hikma, Mylan (now Viatris), and other generic manufacturers spent years attempting to develop generic Advair formulations, with FDA approval of the first truly interchangeable generic not arriving until 2019, more than a decade after the core active ingredient patents expired [27].<\/p>\n\n\n\n

    The inhaler strategy works because it combines molecular protection, formulation protection, device IP, and manufacturing process know-how into a barrier that is genuinely difficult to replicate. Companies like Novartis (Breezhaler), Boehringer Ingelheim (Respimat soft mist inhaler), and AstraZeneca (Turbuhaler) have built proprietary device platforms that they continue to load with new molecular entities, creating franchises where the device technology itself carries commercial value independent of the current active ingredient.<\/p>\n\n\n\n

    Transdermal Drug Delivery<\/strong><\/h3>\n\n\n\n

    Transdermal patches convert oral or injectable drugs into topical delivery systems that release drug at a controlled rate through the skin. The technology is well-established for drugs including fentanyl (Duragesic), nicotine (Nicoderm), estradiol (Vivelle-Dot, Climara), and rotigotine (Neupro), but each transdermal product requires specific formulation work matching the molecule’s physicochemical properties to the skin permeation requirements.<\/p>\n\n\n\n

    Noven Pharmaceuticals built its commercial model primarily on transdermal delivery technology. Its Vivelle-Dot estradiol patch used a proprietary matrix formulation enabling the smallest patch size in its class while maintaining efficacy, generating IP protection around the formulation and application properties [28]. When estradiol itself faced generic competition, the specific transdermal formulation and device design provided differentiation that pure molecular competition could not immediately replicate.<\/p>\n\n\n\n

    The Neupro (rotigotine) patch for Parkinson’s disease and restless leg syndrome represents a particularly instructive case. UCB developed the patch formulation because rotigotine has poor oral bioavailability, making continuous transdermal delivery the most clinically appropriate route. The patch formulation required a unique silicon-based pressure-sensitive adhesive matrix, and UCB’s patents covered both the adhesive system and methods of treatment [29]. Generic entry faced not just formulation challenges but the practical difficulty of replicating a specialized adhesive matrix without infringing the patent claims.<\/p>\n\n\n\n

    Long-Acting Injectable Formulations<\/strong><\/h3>\n\n\n\n

    Depot formulations, drugs that are injected and then slowly released over days, weeks, or months, have become commercially important in psychiatry, oncology, and endocrinology. They address adherence challenges for conditions where daily oral dosing is problematic and create formulation complexity that resists straightforward generic replication.<\/p>\n\n\n\n

    Janssen’s Invega Sustenna (paliperidone palmitate), a once-monthly injectable suspension for schizophrenia, converted oral paliperidone extended-release tablets into a long-acting formulation with its own patent estate covering the palmitate ester prodrug, the nanoparticle suspension formulation, and the dosing regimen [30]. Paliperidone itself is the active metabolite of risperidone, meaning Janssen had already executed one design-around (oral metabolite) and then executed a second (injectable long-acting version of the metabolite). Invega Hafyera, a six-monthly paliperidone palmitate injection, added another layer of formulation innovation and IP coverage. The net effect was a product franchise extending well beyond the original risperidone composition patent into a generation of distinct formulated products, each with its own patent protection and clinical differentiation argument.<\/p>\n\n\n\n

    \n\n\n\n

    New Indications: Repurposing Within the Lifecycle Management Frame<\/strong><\/h2>\n\n\n\n

    Developing a new indication for an approved drug, particularly when supported by robust clinical data, is among the most straightforward design-around strategies from a regulatory standpoint. The compound’s safety profile is already established, its manufacturing is scaled, and the incremental cost of new Phase 2 and Phase 3 trials is substantially lower than developing a new molecular entity from scratch.<\/p>\n\n\n\n

    New indications generate method-of-use patents, which claim the specific use of a known compound for a new treatment purpose. Method-of-use patents are weaker than composition-of-matter patents because a generic manufacturer can file an ANDA for the original indication with a label that ‘carves out’ the patented new indication. This ‘skinny label’ approach allows generic entry on the original indication while technically not infringing the method-of-use patent for the new indication. Whether prescribers and pharmacists will effectively honor that label distinction is another matter.<\/p>\n\n\n\n

    The Skinny Label Problem<\/strong><\/h3>\n\n\n\n

    The skinny label dynamic was tested extensively in litigation involving carvedilol (Coreg, GlaxoSmithKline). GSK held a method-of-use patent for treating congestive heart failure with carvedilol, a use that was added to the label after the original approval for hypertension. Generic manufacturer Apotex filed an ANDA with a skinny label that omitted the heart failure indication. GSK sued, arguing that even a skinny label did not prevent infringement because physicians would prescribe generic carvedilol for heart failure regardless of what the generic label said [31].<\/p>\n\n\n\n

    The Federal Circuit’s 2021 decision in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. created significant concern in the generic industry by holding that Teva could be liable for induced infringement despite using a skinny label, based on its marketing materials suggesting generic carvedilol could substitute for all uses of Coreg [32]. The decision has since been reheard and its implications remain contested, but it illustrates the extent to which method-of-use patent litigation has become a significant barrier to generic entry even for products with clearly expired composition patents.<\/p>\n\n\n\n

    Oncology Indication Expansion<\/strong><\/h3>\n\n\n\n

    Oncology has seen particularly aggressive use of indication expansion as a lifecycle management strategy, in part because cancer subtypes can qualify as orphan conditions, generating seven-year orphan exclusivity for each distinct indication. A drug approved for multiple cancer types can accumulate layers of orphan exclusivity covering different patient populations, each independently blocking generic entry for that use.<\/p>\n\n\n\n

    Merck’s pembrolizumab (Keytruda) illustrates how indication expansion can build commercial scale that far exceeds the original approval. Pembrolizumab was first approved for advanced melanoma in 2014 [33]. By 2025, it held more than forty FDA approvals across multiple tumor types, including non-small cell lung cancer, head and neck cancer, gastric cancer, colorectal cancer, cervical cancer, and numerous others. Each approval was supported by a separate clinical program, generated new clinical data, and added method-of-use patent claims to an already substantial patent portfolio. The commercial result, Keytruda exceeding $25 billion in annual global sales, reflects both the clinical breadth of PD-1 inhibition as a mechanism and the systematic expansion strategy that Merck pursued across a decade [34].<\/p>\n\n\n\n

    \n\n\n\n

    The Legal Architecture: Building a Defensible Patent Thicket<\/strong><\/h2>\n\n\n\n

    A single patent on a reformulated product may be an insufficient defense against a well-resourced generic manufacturer with experienced patent litigators. The companies that successfully extend their commercial franchises typically do so by building patent estates where the aggregate burden on a generic challenger is substantial, even if any individual patent might be vulnerable to validity challenge.<\/p>\n\n\n\n

    Orange Book Listing Strategy<\/strong><\/h3>\n\n\n\n

    The decision about which patents to list in the Orange Book, and in what sequence, is a strategic judgment with direct commercial consequences. Every Orange Book-listed patent that covers the approved drug product, drug substance, or an approved method of use triggers the Paragraph IV certification process when a generic files an ANDA. Each such certification potentially triggers a 30-month stay of FDA approval and requires the generic to litigate patent validity or non-infringement.<\/p>\n\n\n\n

    Companies managing mature franchises typically list the maximum defensible set of patents in the Orange Book, covering formulation details, release mechanisms, specific polymorphs or salt forms, and methods of treatment. The strategic goal is to maximize the number of Paragraph IV certifications a generic filer must make, increasing litigation costs and timelines. Each additional patent in the Orange Book listing is a potential 30-month stay trigger, creating cumulative delay that may exceed the remaining commercial life of any individual patent.<\/p>\n\n\n\n

    The FDA has authority under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to delist patents from the Orange Book if it determines they do not meet listing requirements [35]. That authority has been used more actively in recent years following FTC enforcement initiatives targeting ‘improper’ Orange Book listings. In 2023, the FTC filed patent listing challenges against multiple brand manufacturers, arguing that certain Orange Book-listed patents did not meet the statutory criteria for listing, particularly for combination device-drug products where device component patents were listed for drugs [36].<\/p>\n\n\n\n

    Inter Partes Review and the Post-Grant Challenge Environment<\/strong><\/h3>\n\n\n\n

    The America Invents Act of 2011 created the inter partes review (IPR) process at the Patent Trial and Appeal Board (PTAB), allowing any party to challenge the validity of an issued patent on grounds of anticipation or obviousness based on prior art patents and printed publications [37]. IPR proceedings have fundamentally changed the economics of pharmaceutical patent litigation.<\/p>\n\n\n\n

    Before IPR, a patent challenger’s primary forum was federal district court litigation, where patent validity questions were expensive to litigate and juries were unpredictable. PTAB IPR proceedings are faster (typically resolved within 12 to 18 months), cheaper than full district court litigation, and decided by technically sophisticated administrative patent judges rather than juries. The result has been a substantial increase in the number of pharmaceutical patents challenged through IPR, with generic manufacturers and, increasingly, hedge funds and patent challengers using IPR to attack formulation, method-of-use, and secondary patents that might otherwise have survived district court challenge.<\/p>\n\n\n\n

    Brand manufacturers have responded by designing patent claims specifically to be robust against IPR challenge, avoiding prior art pitfalls that would enable an anticipation or obviousness finding. The claim drafting choices made at the time of patent filing, which must anticipate challenges that may not materialize for years, have become a specialized discipline combining patent law expertise with deep knowledge of the prior art literature in each relevant formulation science area.<\/p>\n\n\n\n

    The 505(b)(2) NDA Pathway<\/strong><\/h3>\n\n\n\n

    For reformulated products that cannot use the ANDA abbreviated pathway because they differ materially from the reference listed drug, the FDA’s 505(b)(2) NDA pathway allows sponsors to rely on the FDA’s prior findings of safety and efficacy for the original drug while submitting new data for the modified product [38]. This pathway is critical for modified-release formulations, new routes of administration, and new combinations, because it allows a middle ground between a full new drug application and a pure bioequivalence-based ANDA.<\/p>\n\n\n\n

    Products approved via 505(b)(2) receive the same regulatory exclusivities as other NDA products, including three-year clinical investigation exclusivity for new clinical studies that were essential to approval. They are listed in the Orange Book with their relevant patents. Generic manufacturers seeking to copy a 505(b)(2) product must file ANDAs referencing the 505(b)(2) product as the reference listed drug, or must file their own 505(b)(2) applications if the modified product cannot be shown bioequivalent to the prior form through conventional testing.<\/p>\n\n\n\n

    The 505(b)(2) pathway has been used extensively in lifecycle management programs. Prodrugs, active metabolites, new salt forms, fixed-dose combinations, and new delivery system formulations all potentially qualify for 505(b)(2) approval when they differ materially from the original reference drug. Understanding which design-around approaches can access 505(b)(2) versus those that must go through full NDA development is a core element of lifecycle management planning.<\/p>\n\n\n\n

    \n\n\n\n

    Competitive Intelligence: How Companies Track and Respond to Generic Threats<\/strong><\/h2>\n\n\n\n

    No design-around strategy operates in isolation from the competitive landscape. A company investing in a new formulation must understand not only its own patent position but the status of any pending generic ANDAs, Paragraph IV certification history, and litigation timelines that will determine when generic entry actually occurs.<\/p>\n\n\n\n

    Paragraph IV Certifications as Early Warning Signals<\/strong><\/h3>\n\n\n\n

    When a generic manufacturer files an ANDA with a Paragraph IV certification against an Orange Book-listed patent, it is required to notify the brand manufacturer and patent holder within 20 days of FDA notification [39]. That notification triggers the brand’s option to file a patent infringement suit within 45 days to obtain the 30-month stay. The Paragraph IV filing itself, however, is a public signal that a generic manufacturer has assessed the patent as vulnerable to challenge and is prepared to litigate.<\/p>\n\n\n\n

    Tracking Paragraph IV filings across a company’s portfolio, and across the portfolios of competitors and partners, is a routine function of pharmaceutical IP departments. Services like DrugPatentWatch aggregate Paragraph IV filing history into searchable databases that allow companies to see at a glance which of their patents have been challenged, by whom, and on what timeline. This visibility is essential for making investment decisions about which design-around programs to fund and which existing formulations to defend through litigation versus accepting generic entry.<\/p>\n\n\n\n

    The first generic manufacturer to file an ANDA with a Paragraph IV certification and survive litigation (or settle on terms that allow early entry) earns 180 days of generic market exclusivity before subsequent generic entrants can receive FDA approval [40]. That 180-day exclusivity period creates strong incentives for generic manufacturers to be first filers, driving early Paragraph IV challenges against any commercially significant patent. A brand company that can identify likely first filers early, through patent monitoring, ANDA filings, and litigation history, is better positioned to evaluate whether litigation is worth pursuing or whether settlement with an authorized generic arrangement makes more financial sense.<\/p>\n\n\n\n

    Authorized Generics as a Defensive Tool<\/strong><\/h3>\n\n\n\n

    An authorized generic is a version of a brand drug sold at generic prices under the brand manufacturer’s NDA by either the brand itself or a third-party partner. Launching an authorized generic at the time of generic entry is a well-established strategy to capture a share of the generic market rather than ceding it entirely, while simultaneously reducing the commercial value of the 180-day first-filer exclusivity period by competing against the first-filing generic during its exclusivity window.<\/p>\n\n\n\n

    A first-filing generic earns its 180-day exclusivity specifically in the window before subsequent generics can enter. If the brand launches an authorized generic during that same window, the first-filer is competing against both the brand and an authorized generic priced at or near the generic price. This significantly reduces the financial reward of the 180-day exclusivity and can deter generic entry in some cases, particularly for smaller-volume markets where the first-filer’s litigation investment may not be fully recouped if the authorized generic captures substantial market share [41].<\/p>\n\n\n\n

    Pfizer’s authorized generic strategy for Lipitor (atorvastatin) at the time of patent expiration in 2011 was among the most visible deployments of this approach. Pfizer partnered with Watson Pharmaceuticals (now Allergan\/Teva) to distribute an authorized generic simultaneously with the first-filer generic entry, maintaining manufacturing revenue and limiting the extent to which the brand’s market share collapsed purely to the benefit of independent generic manufacturers [42].<\/p>\n\n\n\n

    \n\n\n\n

    Where Lifecycle Management Goes Wrong<\/strong><\/h2>\n\n\n\n

    Not every design-around strategy succeeds. Many fail for predictable reasons that careful planning could have addressed. Understanding the failure modes is as important as understanding the success stories.<\/p>\n\n\n\n

    Clinical Differentiation Failures<\/strong><\/h3>\n\n\n\n

    The most common failure mode is investing in a formulation change that cannot demonstrate meaningful clinical differentiation from the prior product. A modified-release formulation that offers pharmacokinetic improvements on paper but does not translate those improvements into patient outcomes data will struggle to justify premium pricing, secure formulary placement, or convince prescribers to actively switch patients.<\/p>\n\n\n\n

    Forest Laboratories’ experience with Namenda XR (memantine extended-release) illustrates both the commercial potential and the legal risk of lifecycle management without compelling clinical differentiation. Namenda IR was approved for Alzheimer’s disease, and Namenda XR offered once-daily versus twice-daily dosing through a modified-release formulation. Forest moved aggressively to transition patients from IR to XR and then announced it would withdraw Namenda IR from the market before generics entered [43]. The State of New York sued, arguing that the forced switch from IR to XR was an anticompetitive attempt to prevent patients from accessing generic memantine once IR patents expired. The court enjoined the IR withdrawal, ruling that the strategy harmed competition without adequate clinical justification for mandatory conversion [44].<\/p>\n\n\n\n

    The Namenda case demonstrates that formulation strategy and legal strategy must be developed jointly. A new formulation with genuine clinical advantages supports a voluntary market transition that antitrust law is unlikely to challenge. A forced switch from a functionally equivalent prior product to a new one, timed to coincide with generic entry on the prior product, is precisely the kind of conduct courts and regulators will scrutinize.<\/p>\n\n\n\n

    Patent Validity Failures<\/strong><\/h3>\n\n\n\n

    Secondary patents covering formulations, methods of use, or delivery systems are generally weaker than composition-of-matter patents and more vulnerable to validity challenge. A lifecycle management strategy built heavily on secondary patent protection must account for the realistic probability that those patents will not survive inter partes review or district court challenge.<\/p>\n\n\n\n

    Purdue Pharma’s OxyContin reformulation to abuse-deterrent technology is an instructive case in both directions. Purdue developed a new formulation of oxycodone extended-release using polyethylene oxide technology that makes the tablet resistant to crushing and dissolving, reducing abuse via insufflation and injection [45]. The abuse-deterrent formulation had genuine public health value, supported FDA approval, generated new patent protection, and enabled Purdue to petition the FDA to remove the original formulation from the market (which the FDA declined to do with AB-rated equivalence). The clinical rationale for the reformulation was more defensible than many purely commercially motivated formulation changes.<\/p>\n\n\n\n

    Separately, many of the secondary patents Purdue had listed in the Orange Book for earlier versions of OxyContin were successfully challenged by generic manufacturers in patent litigation, with several patents being found invalid. The lesson is that patent thicket strategies require each layer of protection to be independently defensible, not merely numerous.<\/p>\n\n\n\n

    Payer Resistance<\/strong><\/h3>\n\n\n\n

    The United States pharmacy benefit management and formulary management environment has become increasingly resistant to paying premium prices for reformulated products that are perceived as clinically similar to cheaper alternatives. Express Scripts, CVS Caremark, and OptumRx have developed sophisticated formulary exclusion programs that remove branded drugs from preferred formulary status when clinical evidence does not support incremental value over generics or biosimilars [46].<\/p>\n\n\n\n

    A reformulated product that wins FDA approval but fails to demonstrate outcomes-level clinical differentiation may find itself excluded from major formularies regardless of its patent status. Patent protection prevents generic entry but does not force payers to reimburse the brand at premium prices. A company that invests heavily in a design-around strategy without simultaneously generating comparative effectiveness data sufficient to support payer reimbursement has completed only half the strategic task.<\/p>\n\n\n\n

    \n\n\n\n

    The Biosimilar Parallel: Design-Arounds in Biologics<\/strong><\/h2>\n\n\n\n

    The design-around dynamics that shape small molecule pharmaceutical lifecycle management are playing out in an intensified form in the biologics space. As patents expire on first-generation monoclonal antibodies and other biologics, brand manufacturers face a new category of competitor: biosimilar developers who can approximate, but cannot exactly replicate, the originator biologic.<\/p>\n\n\n\n

    The Biologics Price Competition and Innovation Act of 2010 created an abbreviated regulatory pathway for biosimilar approval, analogous to the Hatch-Waxman ANDA pathway for small molecules [47]. Unlike small molecule generic equivalence, which requires demonstrating pharmaceutical equivalence and bioequivalence, biosimilar approval requires demonstrating that there are no clinically meaningful differences in safety, purity, and potency compared to the reference product. That higher bar reflects the structural complexity of biological molecules.<\/p>\n\n\n\n

    AbbVie’s defense of Humira (adalimumab) represents the most extensive biologics lifecycle management effort on record. Humira became the world’s best-selling drug, generating over $20 billion in annual global revenue, supported by a patent estate that litigation analysts at various points described as comprising over 130 patents covering the antibody itself, its formulation, its manufacturing process, and its methods of treatment [48]. AbbVie used the totality of that patent estate to negotiate settlements with virtually every major biosimilar developer, granting each a specific U.S. market entry date rather than litigating to a final outcome.<\/p>\n\n\n\n

    The settlements effectively controlled the timing of biosimilar competition in the United States, with most biosimilars entering in January 2023 despite Humira’s European biosimilar market having opened several years earlier [49]. Simultaneously, AbbVie had developed Skyrizi (risankizumab) and Rinvoq (upadacitinib) as successor immunology products with distinct mechanisms, targets, and indications, building the commercial foundation for its post-Humira revenue base before biosimilar entry arrived.<\/p>\n\n\n\n

    That combination, patent thicket defense of the existing product plus proactive development of successor products with independent IP, is the template that most large biologics companies now follow.<\/p>\n\n\n\n

    \n\n\n\n

    Building the Design-Around Program: Organizational and Process Requirements<\/strong><\/h2>\n\n\n\n

    Executing a successful design-around strategy requires cross-functional coordination across R&D, regulatory affairs, legal, market access, and commercial teams. It also requires organizational willingness to invest in cannibalizing the existing product for a reformulated successor before the existing product’s revenue base has eroded, which runs against the natural incentive structures in most commercial organizations.<\/p>\n\n\n\n

    The Five-Year Planning Horizon<\/strong><\/h3>\n\n\n\n

    Patent expiration planning for major franchises should begin no later than five years before the anticipated expiration date of the core composition patent. That horizon provides time for formulation development and clinical evaluation, manufacturing scale-up for a new formulation, regulatory submission and review, patent prosecution for new formulation claims, payer strategy development for the successor product, and physician education and formulary positioning work.<\/p>\n\n\n\n

    The gap between when planning should start and when it actually starts in most large pharmaceutical companies tends to be driven by the internal economics of the existing franchise. Product teams managing a currently profitable product have limited incentive to prioritize activities that will ultimately replace their own product with something that may be priced lower or address a smaller patient population. Creating a separate lifecycle management function with its own P&L responsibility and incentive structure, rather than embedding lifecycle decisions in the existing brand team, is an organizational solution that several companies have implemented with meaningful results.<\/p>\n\n\n\n

    Integrating Competitive Intelligence into the Planning Process<\/strong><\/h3>\n\n\n\n

    Effective lifecycle management planning requires continuous monitoring of the competitive landscape, not merely a point-in-time patent analysis. A brand company needs to know when its first Paragraph IV certification arrives, which generic manufacturers are investing in formulation development for its compound, whether any third parties are filing IPR petitions against its Orange Book-listed patents, and what regulatory activities are pending at the FDA that might affect its competitive position.<\/p>\n\n\n\n

    This monitoring function has become increasingly sophisticated and technology-dependent. Platforms like DrugPatentWatch provide real-time updates on FDA ANDA filings, Orange Book changes, and litigation events. Patent monitoring services track new filings and office actions relevant to specific compounds. Clinical trial registries reveal whether competitors are developing alternative formulations or combinations that might compete with the company’s own lifecycle management plans.<\/p>\n\n\n\n

    The competitive intelligence gathered from these sources directly informs investment decisions in the design-around program. A company that discovers a generic manufacturer has already begun formulation development for its compound two years ahead of schedule needs to accelerate its own reformulation timeline or accept earlier-than-anticipated generic competition. A company that learns a competitor is filing for a similar combination product needs to evaluate whether its own combination program can reach market first or whether its IP strategy adequately covers the approach.<\/p>\n\n\n\n

    The Global Dimension<\/strong><\/h3>\n\n\n\n

    Patent protection and regulatory exclusivity are national or regional in scope. A design-around strategy that works in the United States may not translate directly to European, Japanese, or emerging markets where patent law, data exclusivity rules, and regulatory pathways differ materially. Companies managing global franchises must conduct lifecycle management planning in each major market independently, which multiplies the analytical complexity but also creates opportunities for differentiated strategies across geographies.<\/p>\n\n\n\n

    In Europe, the European Medicines Agency’s centralized procedure provides a single approval that is valid across EU member states, but patent protection is managed at the national level. The supplementary protection certificate (SPC) mechanism extends patent protection for up to five additional years to compensate for the time spent in regulatory review, providing an important additional exclusivity layer that does not exist in the U.S. patent system [50]. A company managing European lifecycle strategy must account for SPC expiration dates in addition to basic patent terms, and for the separate regulatory data exclusivity periods provided under European law.<\/p>\n\n\n\n

    Developing markets present a different challenge. India, Brazil, and South Africa have weaker or differently structured pharmaceutical patent systems that may provide less protection for formulation or secondary patents than the United States or EU. A design-around strategy based on formulation patents that would be fully defensible in the United States may provide little meaningful protection in markets where those patents are challenged under different legal standards or simply not enforced with comparable rigor.<\/p>\n\n\n\n

    \n\n\n\n

    Antitrust Boundaries: Where Lifecycle Management Becomes Product Hopping<\/strong><\/h2>\n\n\n\n

    The line between legitimate lifecycle management and anticompetitive ‘product hopping’ is contested legal and policy territory. Brand manufacturers argue that they have an absolute right to improve their products and compete on the merits, and that generic manufacturers’ ability to design around expiring patents is itself a form of competition. Regulators and courts have taken a more nuanced view, distinguishing between product improvements that add genuine value and formulation changes designed primarily to switch patients before generic entry and thereby deny generic manufacturers the opportunity to compete for the established patient base.<\/p>\n\n\n\n

    The FTC’s policy framework for evaluating product hopping focuses on two questions: whether the new product is a genuine improvement, and whether the brand manufacturer’s conduct goes beyond legitimate competition to affirmatively suppress generic entry [51]. Announcing withdrawal of the prior version from the market at the moment of generic entry, engaging in exclusive dealings with pharmacy benefit managers to block generic substitution for the prior version, or contractually penalizing wholesalers who stock the prior generic are examples of conduct that goes beyond the product improvement itself.<\/p>\n\n\n\n

    European competition law has taken a comparably active view. The European Commission’s 2009 pharmaceutical sector inquiry documented extensive practices including defensive patent thicket building, settlement agreements with generic manufacturers that delayed entry, and ANDA lifecycle management strategies that the Commission characterized as raising competition concerns [52]. Subsequent enforcement actions against companies including Servier (perindopril) and Lundbeck (citalopram) resulted in substantial fines for pay-for-delay settlement agreements that delayed generic entry in exchange for value transfer from brand to generic [53].<\/p>\n\n\n\n

    A design-around strategy that cannot withstand antitrust scrutiny is not a strategy, it is a liability. Companies need legal counsel engaged in lifecycle management planning from the outset, not brought in after the commercial strategy has been finalized. The clinical justification for any new formulation must be documented contemporaneously, not constructed retroactively when litigation arrives.<\/p>\n\n\n\n

    \n\n\n\n

    Case Study: Venlafaxine XR and the Anatomy of a Successful Extended-Release Defense<\/strong><\/h2>\n\n\n\n

    Wyeth’s management of the venlafaxine franchise across two decades offers a detailed case study of both the potential and the limits of extended-release design-around strategy.<\/p>\n\n\n\n

    Venlafaxine IR (Effexor) was approved for depression in 1993 and generated substantial revenue through the late 1990s. Wyeth developed venlafaxine XR (Effexor XR) using a capsule-within-a-capsule extended-release technology that allowed once-daily dosing versus the twice or thrice-daily dosing of the IR formulation [54]. Effexor XR was approved in 1997 and rapidly cannibalized the IR franchise, reaching over $3 billion in annual U.S. sales.<\/p>\n\n\n\n

    The XR formulation was protected by patents covering the specific extended-release bead technology and the once-daily dosing method. When those patents were challenged by Teva and other generic manufacturers through Paragraph IV filings, Wyeth sued, triggering 30-month stays. The subsequent litigation resolved in Wyeth’s favor on some patents and against it on others, but the extended-release formulation had already established overwhelming commercial dominance over the IR version. By the time generic venlafaxine XR entered the market, the IR formulation was commercially negligible and the brand had been enjoying XR revenues for over a decade.<\/p>\n\n\n\n

    The lesson is not that the patents were impenetrable, they were eventually challenged successfully, but that the combination of formulation science, clinical differentiation (once-daily dosing with meaningful tolerability improvements), and IP protection created a commercially durable franchise that extracted substantial additional value from the underlying molecular discovery. The formulation investment was profitable on its own terms independent of how many years it delayed generic entry.<\/p>\n\n\n\n

    \n\n\n\n

    Emerging Trends Shaping the Next Decade of Design-Around Strategy<\/strong><\/h2>\n\n\n\n

    Several developments are reshaping the environment in which design-around strategies operate, requiring companies to adapt approaches that worked reliably in the prior decade.<\/p>\n\n\n\n

    Real-World Evidence Requirements for Payer Reimbursement<\/strong><\/h3>\n\n\n\n

    Pharmacy benefit managers and government payers increasingly require real-world evidence of clinical differentiation, not merely Phase 3 registration trial data, before granting preferred formulary status to reformulated products. This creates additional investment requirements for lifecycle management programs: beyond generating the clinical data needed for FDA approval, companies need to design post-approval evidence generation strategies that will satisfy payer requirements.<\/p>\n\n\n\n

    For companies with resources to invest in real-world evidence, this trend actually strengthens the defensibility of genuine formulation innovation. A once-daily formulation that demonstrates measurably better adherence and outcomes in a large real-world dataset is far more difficult to dislodge from formulary position than one supported only by pharmacokinetic bioequivalence data.<\/p>\n\n\n\n

    AI-Assisted Formulation Development<\/strong><\/h3>\n\n\n\n

    Machine learning tools are accelerating the early stages of formulation development, enabling companies to screen more chemical and formulation space in less time and with less experimental investment. The same tools are available to generic manufacturers, however, meaning the barrier to developing bioequivalent formulations using alternative approaches may be lower in the next decade than it was in the prior one.<\/p>\n\n\n\n

    Companies investing in design-around programs need to account for the possibility that AI-accelerated formulation development will shorten the timeline between expiring brand patents and credible generic or biosimilar competition. The answer is not to avoid formulation innovation but to ensure that the clinical and regulatory dimensions of lifecycle management, which AI cannot accelerate, are given as much investment as the formulation science itself.<\/p>\n\n\n\n

    The Inflation Reduction Act and Its Patent Implications<\/strong><\/h3>\n\n\n\n

    The Inflation Reduction Act of 2022 introduced Medicare drug price negotiation for a select list of single-source drugs without generic or biosimilar competition [55]. The law establishes eligibility timelines based on whether a drug is a small molecule (nine years post-approval) or a biologic (thirteen years post-approval). Critics, including major brand manufacturers, have argued that this structure creates an incentive to abandon small molecule drug development in favor of biologics, and within small molecules, to extend commercial periods through reformulation and secondary patent strategies that extend the period before negotiation eligibility.<\/p>\n\n\n\n

    Whether the IRA will materially change lifecycle management strategy is being worked out in corporate planning cycles across the industry. The differential treatment of small molecules versus biologics creates a structural incentive for companies to develop molecular entities that qualify as biologics wherever scientifically feasible. Within small molecules, the nine-year negotiation eligibility clock creates pressure to maximize the clinical and commercial value of the initial exclusivity period and to develop successor products with genuinely distinct clinical profiles rather than relying on formulation-only differentiation.<\/p>\n\n\n\n

    \n\n\n\n

    Practical Guidance: Executing a Design-Around Audit<\/strong><\/h2>\n\n\n\n

    For a pharmaceutical company beginning a design-around planning process for a major franchise, the following sequence of analysis is a practical starting point.<\/p>\n\n\n\n

    The first step is a comprehensive patent landscape review covering all Orange Book-listed patents, their claim scope and expiration dates, any pending IPR petitions, Paragraph IV certification history, and any litigation outcomes. Services like DrugPatentWatch consolidate much of this information in accessible format and can accelerate the initial landscape mapping from weeks of manual research to hours of structured database review.<\/p>\n\n\n\n

    The second step is a formulation option matrix: a systematic evaluation of which design-around approaches are scientifically feasible for the compound in question, which have existing third-party patent coverage that would need to be licensed or worked around, and which could support new proprietary patent claims. This step requires collaboration between formulation scientists, patent counsel, and regulatory affairs specialists to evaluate not just what is scientifically possible but what is patentable and approvable.<\/p>\n\n\n\n

    The third step is a clinical differentiation assessment: for each formulation option that passes the scientific and IP feasibility screens, what clinical data would be required to demonstrate meaningful differentiation from the existing product and from likely generic competition? What is the timeline and cost of generating that data? What are the probability of success estimates for the clinical program?<\/p>\n\n\n\n

    The fourth step is commercial modeling: for each viable design-around option, what is the projected revenue impact of the new formulation compared to the scenario of accepting generic entry with no defensive action? This modeling needs to incorporate realistic assumptions about payer acceptance, prescriber conversion rates, authorized generic cannibalization, and the timeline uncertainty inherent in patent litigation outcomes.<\/p>\n\n\n\n

    That four-step process provides the analytical foundation for a defensible investment decision. It will not eliminate uncertainty, but it will make explicit the assumptions underlying each strategic choice and create a documented record of the clinical and commercial rationale that may be important if the strategy is later challenged on antitrust grounds.<\/p>\n\n\n\n

    \n\n\n\n

    Key Takeaways<\/strong><\/h2>\n\n\n\n
      \n
    • Patent expiration is a scheduled event, not an emergency. Companies that begin design-around planning five or more years before composition patent expiration consistently outperform those that react when generic entry is imminent.<\/li>\n\n\n\n
    • Formulation innovation is most defensible, legally and commercially, when it produces genuine clinical differentiation. Pharmacokinetic improvements that translate into measurable patient outcomes data are substantially stronger than reformulations supported only by in vitro dissolution profiles.<\/li>\n\n\n\n
    • Patent thicket strategies work by accumulating complexity for challengers, but each layer must be independently defensible. A large number of weak patents does not substitute for a smaller number of valid, well-drafted ones.<\/li>\n\n\n\n
    • Regulatory exclusivity and patent protection operate on parallel tracks. NCE exclusivity, pediatric exclusivity, orphan drug exclusivity, and three-year clinical investigation exclusivity can each add meaningful protection independent of the patent estate.<\/li>\n\n\n\n
    • Competitive intelligence platforms, including DrugPatentWatch, are essential infrastructure for lifecycle management planning, enabling companies to track Paragraph IV filings, patent expiration timelines, and ANDA activity in real time rather than discovering competitive threats after they have materialized.<\/li>\n\n\n\n
    • Antitrust risk is real and increasing. Design-around strategies must be documented and justified on clinical and scientific grounds from the outset, with legal counsel embedded in the planning process rather than consulted after commercial decisions have been made.<\/li>\n\n\n\n
    • The biosimilar context amplifies all of these dynamics for biologic products, where the combination of molecular complexity, patent thicket depth, and extended regulatory pathways creates different but equally important design-around opportunities.<\/li>\n<\/ul>\n\n\n\n
      \n\n\n\n

      Frequently Asked Questions<\/strong><\/h2>\n\n\n\n

      1. What is the difference between a composition-of-matter patent and a formulation patent in pharmaceutical lifecycle management?<\/strong><\/h3>\n\n\n\n

      A composition-of-matter patent claims the chemical structure of the active pharmaceutical ingredient itself, making it the broadest and strongest form of pharmaceutical IP protection. Any drug product containing that molecule infringes the patent regardless of how it is formulated. A formulation patent, by contrast, claims a specific way of preparing the drug, such as a particular extended-release mechanism, a specific particle size distribution, or a specific combination with other excipients. Formulation patents allow generic manufacturers to develop the same active molecule in a different formulation without infringing, provided the new formulation is bioequivalent to the original for regulatory purposes. The strategic implication is that composition-of-matter patents delay all generic competition, while formulation patents delay only generic competition using the same formulation approach.<\/p>\n\n\n\n

      2. How does a Paragraph IV certification affect a brand manufacturer’s design-around timeline?<\/strong><\/h3>\n\n\n\n

      When a generic manufacturer files an ANDA with a Paragraph IV certification against an Orange Book-listed patent, it signals that the generic believes the patent is invalid or will not be infringed by its product. If the brand manufacturer sues within 45 days of notification, FDA approval of the ANDA is automatically stayed for 30 months, providing the brand with additional commercial exclusivity while litigation proceeds. From a design-around perspective, a Paragraph IV certification is both a warning signal and a trigger for accelerating reformulation timelines. A company that receives a Paragraph IV against its primary composition patent on a flagship product now knows with precision that a well-resourced competitor is actively pursuing generic entry, typically within three to four years. That timeline forces prioritization of any lifecycle management investments that could compete with or succeed the existing formulation.<\/p>\n\n\n\n

      3. Can a company lose antitrust immunity for a design-around strategy even if the new formulation is genuinely better?<\/strong><\/h3>\n\n\n\n

      Antitrust analysis under the product-hopping framework focuses primarily on conduct, not product quality. A genuinely superior new formulation does not provide absolute immunity if the company engages in conduct that affirmatively prevents generic competition on the prior version rather than simply competing on the merits of the new product. Announcing withdrawal of the prior formulation from the market at the moment of generic entry, paying physicians to switch patients to the new formulation through arrangements that raise kickback concerns, or contractually restricting pharmacies from dispensing the prior generic are examples of conduct that can expose a company to antitrust liability regardless of the clinical merits of the new formulation. The safe approach is to compete aggressively for new prescriptions and voluntary patient conversion while allowing the prior formulation to remain available for patients and payers who prefer it, even if that limits the speed of the commercial transition.<\/p>\n\n\n\n

      4. What role does the FDA’s 505(b)(2) pathway play in design-around strategy compared to a full NDA?<\/strong><\/h3>\n\n\n\n

      The 505(b)(2) pathway allows a new drug application to rely on existing FDA findings of safety and efficacy for the active ingredient from a prior NDA, supplemented by new data specific to the reformulated product. This substantially reduces the development investment required compared to a full new chemical entity NDA, which must independently demonstrate safety and efficacy from scratch. For design-around strategies based on new formulations of existing compounds, 505(b)(2) is usually the applicable pathway, provided the new formulation differs materially from the reference listed drug such that standard bioequivalence testing is insufficient. Products approved via 505(b)(2) receive three-year clinical investigation exclusivity for new clinical studies essential to approval, can list qualifying patents in the Orange Book, and require generic challengers to file either ANDAs against the 505(b)(2) product as the reference listed drug or their own 505(b)(2) applications for the modified form.<\/p>\n\n\n\n

      5. How should a company think about design-around strategy for a drug approaching the Inflation Reduction Act’s Medicare negotiation eligibility threshold?<\/strong><\/h3>\n\n\n\n

      The IRA’s negotiation eligibility clock starts from first approval and runs independently of patent status. A small molecule drug becomes eligible for negotiation nine years after initial FDA approval if it lacks generic or biosimilar competition; a biologic after thirteen years. Design-around strategies, including new formulations, new indications, and new delivery systems, do not reset this eligibility clock unless the reformulated product is approved as a distinct new drug with a new application number that the CMS treats as a separate product for negotiation purposes. Companies approaching the IRA eligibility window have strong incentives to ensure their lifecycle management investments produce genuinely distinct products with new clinical profiles rather than formulation variants of the same drug, as the latter are unlikely to escape the negotiation framework. Early engagement with CMS’s guidance on how it will treat reformulated products in the negotiation context is essential planning input for any company whose primary franchise is approaching the nine-year threshold.<\/p>\n\n\n\n

      \n\n\n\n

      References<\/strong><\/h2>\n\n\n\n
        \n
      1. IQVIA Institute for Human Data Science. (2024). Global Medicine Spending and Usage Trends: Outlook to 2028<\/em>. IQVIA Holdings.<\/li>\n\n\n\n
      2. Grabowski, H., Long, G., Mortimer, R., & Boyo, A. (2014). Updated trends in US brand-name and generic drug competition. Journal of Medical Economics<\/em>, 17(1), 13\u201319. https:\/\/doi.org\/10.3111\/13696998.2013.840185<\/li>\n\n\n\n
      3. Kaplan, W., & Laing, R. (2005). Local production of pharmaceuticals: industrial policy and access to medicines. Health, Nutrition and Population Discussion Paper<\/em>. World Bank.<\/li>\n\n\n\n
      4. Federal Trade Commission. (2009). Complaint in the Matter of Abbott Laboratories<\/em>. FTC Docket No. C-4297. https:\/\/www.ftc.gov\/enforcement\/cases-proceedings\/081-0182\/abbott-laboratories-fournier-industrie<\/li>\n\n\n\n
      5. Hatch-Waxman Act, Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (1984).<\/li>\n\n\n\n
      6. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations<\/em> (42nd ed.). FDA Orange Book. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/<\/li>\n\n\n\n
      7. Kesselheim, A. S., & Avorn, J. (2013). The most transformative drugs of the past 25 years: A survey of physicians. Nature Medicine<\/em>, 19(1), 4. https:\/\/doi.org\/10.1038\/nm0113-4<\/li>\n\n\n\n
      8. Bogdan, N., & Villiger, R. (2010). Valuation in Life Sciences (3rd ed.). Springer.<\/li>\n\n\n\n
      9. Swanson, D. R. (2003). OROS push-pull technology. Expert Opinion on Drug Delivery<\/em>, 1(1), 13\u201316.<\/li>\n\n\n\n
      10. Janssen Pharmaceutica. (2003). Risperdal Consta full prescribing information<\/em>. Janssen Pharmaceutical Companies of Johnson & Johnson.<\/li>\n\n\n\n
      11. Elan Drug Technologies. (2005). NanoCrystal Technology Platform<\/em>. Elan Corporation Technical Brief.<\/li>\n\n\n\n
      12. Goldberg, M., & Gomez-Orellana, I. (2003). Challenges for the oral delivery of macromolecules. Nature Reviews Drug Discovery<\/em>, 2(4), 289\u2013295.<\/li>\n\n\n\n
      13. Gilead Sciences. (2006). Atripla prescribing information and approval background<\/em>. Gilead Sciences, Inc.<\/li>\n\n\n\n
      14. Pfizer Inc. (2004). Caduet (amlodipine besylate\/atorvastatin calcium) NDA approval and Orange Book listing<\/em>. FDA NDA 021520.<\/li>\n\n\n\n
      15. Woosley, R. L., Chen, Y., Freiman, J. P., & Gillis, R. A. (1993). Mechanism of the cardiotoxic actions of terfenadine. JAMA<\/em>, 269(12), 1532\u20131536.<\/li>\n\n\n\n
      16. Burke, W. J. (2002). Escitalopram. Expert Opinion on Investigational Drugs<\/em>, 11(10), 1477\u20131486.<\/li>\n\n\n\n
      17. Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., & Volberding, P. A. (2018). Antiretroviral drugs for treatment and prevention of HIV infection in adults. JAMA<\/em>, 320(4), 379\u2013396.<\/li>\n\n\n\n
      18. Carrier, M. A., & Kesselheim, A. S. (2018). Clopidogrel and the patent cliff. Stanford Technology Law Review<\/em>, 21(2), 293\u2013334.<\/li>\n\n\n\n
      19. Supreme Court of India. (2013). Novartis AG v. Union of India & Others<\/em>. Civil Appeal Nos. 2706\u20132716 of 2013.<\/li>\n\n\n\n
      20. Food and Drug Administration. (2020). New Drug Exclusivity<\/em>. FDA CDER. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/new-drug-exclusivity<\/li>\n\n\n\n
      21. Best Pharmaceuticals for Children Act of 2002, Pub. L. No. 107-109, 115 Stat. 1408 (2002).<\/li>\n\n\n\n
      22. Food and Drug Administration. (2021). Pediatric Labeling Changes: December 2020 Update<\/em>. FDA CDER Pediatric Studies.<\/li>\n\n\n\n
      23. Orphan Drug Act of 1983, Pub. L. No. 97-414, 96 Stat. 2049 (1983).<\/li>\n\n\n\n
      24. Alexion Pharmaceuticals. (2018). Ultomiris (ravulizumab) FDA approval and product monograph<\/em>. Alexion Pharmaceuticals, Inc.<\/li>\n\n\n\n
      25. Food and Drug Administration. (2019). Frequently Asked Questions: Drug Exclusivity<\/em>. FDA CDER. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/frequently-asked-questions-drug-exclusivity<\/li>\n\n\n\n
      26. Dissanayake, S., & Suggett, J. (2018). A review of the in vitro and in vivo valuation of the aerodynamic performance of dry powder inhaler products: The role of inter-subject variability in regional lung deposition. Expert Opinion on Drug Delivery<\/em>, 15(12), 1195\u20131212.<\/li>\n\n\n\n
      27. Food and Drug Administration. (2019). FDA approves first generic of Advair Diskus to treat asthma and COPD<\/em>. FDA News Release.<\/li>\n\n\n\n
      28. Noven Pharmaceuticals. (2001). Vivelle-Dot (estradiol transdermal system) prescribing information<\/em>. Noven Pharmaceuticals, Inc.<\/li>\n\n\n\n
      29. UCB. (2007). Neupro (rotigotine transdermal system) prescribing information and patent synopsis<\/em>. UCB, Inc.<\/li>\n\n\n\n
      30. Janssen Pharmaceutica. (2009). Invega Sustenna (paliperidone palmitate) extended-release injectable suspension<\/em>. FDA NDA 022264.<\/li>\n\n\n\n
      31. Mead, D. (2018). The patent thicket in pharmaceutical patent law. American University Law Review<\/em>, 67(5), 1479\u20131530.<\/li>\n\n\n\n
      32. GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021).<\/li>\n\n\n\n
      33. Food and Drug Administration. (2014). FDA approves Keytruda for advanced melanoma<\/em>. FDA News Release. https:\/\/www.fda.gov\/news-events\/press-announcements<\/li>\n\n\n\n
      34. Merck & Co., Inc. (2025). 2024 Annual Report: Keytruda global sales data<\/em>. Merck & Co.<\/li>\n\n\n\n
      35. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. No. 108-173, 117 Stat. 2066 (2003).<\/li>\n\n\n\n
      36. Federal Trade Commission. (2023). FTC Challenges Hundreds of Improper Orange Book Patent Listings that May Delay Generic Drug Competition<\/em>. FTC Press Release. https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2023\/09<\/li>\n\n\n\n
      37. Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011).<\/li>\n\n\n\n
      38. Food and Drug Administration. (2019). Guidance for Industry: Applications Covered by Section 505(b)(2)<\/em>. FDA CDER.<\/li>\n\n\n\n
      39. 21 U.S.C. \u00a7 355(j)(2)(B) (Paragraph IV certification notification requirement).<\/li>\n\n\n\n
      40. 21 U.S.C. \u00a7 355(j)(5)(B)(iv) (180-day first-filer exclusivity).<\/li>\n\n\n\n
      41. Carrier, M. A. (2011). Unsettling drug patent settlements: A framework for presumptive illegality. Michigan Law Review<\/em>, 108(1), 37\u201380.<\/li>\n\n\n\n
      42. Herper, M. (2011, November 30). The inside story of the Pfizer-Watson Lipitor deal. Forbes<\/em>.<\/li>\n\n\n\n
      43. New York v. Actavis, PLC, 787 F.3d 638 (2d Cir. 2015).<\/li>\n\n\n\n
      44. New York v. Actavis, PLC, No. 14-4624 (2d Cir. 2015).<\/li>\n\n\n\n
      45. Gao, Y., Bhalerao, M., Draper, B. E., Wooten, J., Bhatt, D. L., & Bhatt, D. (2013). OxyContin reformulation and abuse-deterrent technology. Drug and Alcohol Dependence<\/em>, 130(1\u20133), 30\u201336.<\/li>\n\n\n\n
      46. Fein, A. J. (2019). Drug Channels Report: Formulary Exclusion Lists and Their Commercial Impact<\/em>. Drug Channels Institute.<\/li>\n\n\n\n
      47. Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, tit. VII, 124 Stat. 119 (2010).<\/li>\n\n\n\n
      48. Bessen, J., & Meurer, M. J. (2008). Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk<\/em>. Princeton University Press.<\/li>\n\n\n\n
      49. Cromer, B. (2023, January). AbbVie’s Humira biosimilar strategy and U.S. market opening. Reuters Health.<\/em><\/li>\n\n\n\n
      50. Regulation (EC) No 469\/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products. Official Journal of the European Union<\/em>, L 152, 1\u201310.<\/li>\n\n\n\n
      51. Federal Trade Commission. (2010). Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions<\/em>. FTC Staff Study.<\/li>\n\n\n\n
      52. European Commission. (2009). Pharmaceutical Sector Inquiry Final Report<\/em>. EC Competition DG.<\/li>\n\n\n\n
      53. Court of Justice of the European Union. (2021). Lundbeck v. European Commission<\/em>. Case C-591\/16 P.<\/li>\n\n\n\n
      54. Bezwada, H., & Lippard, J. (2007). Venlafaxine extended-release formulation development and regulatory history. Journal of Controlled Release<\/em>, 119(2), 169\u2013175.<\/li>\n\n\n\n
      55. Inflation Reduction Act of 2022, Pub. L. No. 117-169, 136 Stat. 1818 (2022).<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

        Every major drug company has a clock running in its boardroom. When a blockbuster patent expires, billions in annual revenue […]<\/p>\n","protected":false},"author":1,"featured_media":38729,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38725","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38725"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38725\/revisions"}],"predecessor-version":[{"id":38730,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38725\/revisions\/38730"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38729"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}